GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptinyx Inc (OTCPK:APTX) » Definitions » Earnings per Share (Diluted)

Aptinyx (Aptinyx) Earnings per Share (Diluted) : $-0.98 (TTM As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aptinyx Earnings per Share (Diluted)?

Aptinyx's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-0.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.98.

Aptinyx's EPS (Basic) for the three months ended in Mar. 2023 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.98.

Aptinyx's EPS without NRI for the three months ended in Mar. 2023 was $-0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.98.


Aptinyx Earnings per Share (Diluted) Historical Data

The historical data trend for Aptinyx's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptinyx Earnings per Share (Diluted) Chart

Aptinyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Get a 7-Day Free Trial -2.64 -1.71 -1.02 -1.11 -0.96

Aptinyx Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.26 -0.23 -0.18 -0.31

Competitive Comparison of Aptinyx's Earnings per Share (Diluted)

For the Biotechnology subindustry, Aptinyx's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptinyx's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptinyx's PE Ratio distribution charts can be found below:

* The bar in red indicates where Aptinyx's PE Ratio falls into.



Aptinyx Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Aptinyx's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-64.849-0)/67.716
=-0.96

Aptinyx's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (Q: Mar. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-21.066-0)/67.716
=-0.31

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Aptinyx  (OTCPK:APTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aptinyx Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Aptinyx's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptinyx (Aptinyx) Business Description

Industry
Traded in Other Exchanges
N/A
Address
909 Davis Street, Suite 600, Evanston, IL, USA, 60201
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
Executives
Joan W. Miller director C/O APTINYX INC., 909 DAVIS ST., SUITE 600, EVANSTON IL 60201
Norbert G Riedel director, officer: CEO and President BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Ashish Khanna officer: CFO and CBO 909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Rachel E. Sherman director 909 DAVIS STREET, SUITE 600, EVANSTON IL 60201
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Partners, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Jeffrey Lawrence Schwartz 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Bcip Life Sciences Associates, Lp 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025

Aptinyx (Aptinyx) Headlines

From GuruFocus

Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022

By Business Wire Business Wire 12-20-2021

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

By Business Wire Business Wire 08-12-2022

Aptinyx to Present at the SVB Securities Global Biopharma Conference

By Business Wire Business Wire 01-31-2023